Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144833
Status:
TERMINATED
Last Update Posted:
2007-11-12
First Post:
2005-09-01
Brief Title:
Open Label Study of 908RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase III Randomized Controlled Open-Label Multicentre Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of FosamprenavirLopinavirRitonavir 1400mg533mg133mg Twice Daily and an Increased Dosage Regimen of FPVRTV 1400mg100mg BID Versus the Standard Dosage Regimen of FPVRTV 700mg100mg BID for 24 Weeks in Multiple-PI Experienced HIV-Infected Adults Experiencing Virological Failure
Status:
TERMINATED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Incomplete data
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
For HIV-infected individuals with highly resistant viruses higher drug levels may be required to block the virus This study investigates that concept by comparing the efficacy of standard fosamprenavirritonavir to an increased dose of boosted fosamprenavir and to a combination of fosamprenavir increased doselopinavirritonavir
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None